Meeting
2015 ASCO Annual Meeting
Phase II study of panitumumab, nab-paclitaxel, and carboplatin followed by FEC neoadjuvant chemotherapy for patients with primary HER-2 negative inflammatory breast cancer.
Authors
Naoko Matsuda
The University of Texas MD Anderson Cancer Center, Houston, TX
Naoko Matsuda , Ricardo H. Alvarez , Savitri Krishnamurthy , Jie S. Willey , Xiaoping Wang , Bora Lim , Charla A. Parker , Angela Marx , Gildy Babiera , Daniel J. Booser , James L. Murray , Banu Arun , Abenaa M. Brewster , James M. Reuben , Wendy A. Woodward , Anthony Lucci Jr., Sarah Marie Gainer , Debu Tripathy , Vicente Valero , Naoto T. Ueno
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Triple-Negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Local Therapy
Clinical Trial Registration Number
NCT01036087
Citation
J Clin Oncol 33, 2015 (suppl; abstr 1065)
DOI
10.1200/jco.2015.33.15_suppl.1065
Abstract #
1065
Poster Bd #
179
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Phase II study of panitumumab, nab-paclitaxel, and carboplatin followed by FEC neoadjuvant chemotherapy for patients with primary HER2-negative inflammatory breast cancer.
First Author: Naoko Matsuda
Poster
2014 ASCO Annual Meeting
Randomized phase II study of weekly paclitaxel with or without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA HER2-negative breast cancer.
First Author: Kenji Tamura
Poster
2016 ASCO Annual Meeting
Investigating denosumab as add-on neoadjuvant treatment for hormone receptor-negative, RANK-positive or RANK-negative primary breast cancer and two different nab-Paclitaxel schedules - 2x2 factorial design (GeparX).
First Author: Sherko Kümmel
Poster
2013 ASCO Annual Meeting
Phase II study of neoadjuvant chemotherapy with a metronomic regimen of paclitaxel + cyclophosphamide + capecitabine followed by 5-fluorouracil + epirubicin + cyclophosphamide in operable triple-negative breast cancer (JBCRG-13 study).
First Author: Kenji Higaki